NIDA-SPONSORED MINI-SYMPOSIUM on
Interactions Between Drugs of Abuse and Pharmacotherapeutics Used in the Treatment of Infections, Drug Abuse,
and Mental Disorders
April 13, 2002
Published and unpublished research presented in national and international forums (NIDA/NIH 1999 workshop [/Meetigns/Interactions.html]; 2nd International Workshop on Clinical Pharmacology of HIV Therapy, Noordwijk, the Netherlands, April 2001) suggests that there are significant pharmacokinetic and pharmacodynamic interactions among various anti-infective medications used in the treatment of infections including HIV, hepatitis C, and tuberculosis, resulting in significant potential for adverse health consequences. However, very few studies have been published or presented on interactions between drugs of abuse (e.g., cocaine, marijuana, opiates, amphetamines, and misused benzodiazepines), agents used to treat substance abuse (e.g., methadone, LAAM, buprenorphine), and antiretroviral pharmacotherapeutic agents. Based on these facts, Dr. Charles Flexner of Johns Hopkins School of Medicine and Jag Khalsa, Ph.D. of NIDA's Center on AIDS and Other Medical Consequences of Drug Abuse (CAMCODA), in collaboration with Dr. Frank Vocci of the Division of Treatment and Research Development (DTRD) and Dr. Steve Gust of the Office of the Director (OD, NIDA), organized a mini-symposium at the 3rd International Workshop on Clinical Pharmacology of HIV Therapy, Washington, DC, April 13, 2002, where experts in HIV pharmacology, substance abuse, pharmacogenomics, and pharmacokinetic modeling presented current data on the subject of drug-drug interactions. The article below summarizes the six presentations made at the well-attended mini-symposium.
Chair: Charles W. Flexner, M.D., Johns Hopkins University School of Medicine, Baltimore, Maryland.
Co-chair: Jag H. Khalsa, Ph.D., Center on AIDS & Other Medical Consequences of Drug Abuse (CAMCODA), National Institute on Drug Abuse, NIH, Bethesda, Maryland.
Charles Flexner, M.D., Ph.D.
Associate Professor of Medicine & Pharmacology
Johns Hopkins University School of Medicine
Gerald Friedland, M.D.
Professor of Medicine and Epidemiology & Public Health
Director, Yale AIDS Program
135 College Street, suite 323
New Haven, CT 06510-2483
John Gerber, M.D.
Professor of Medicine and Pharmacology
Division of Clinical Pharmacology
University of Colorado Health Sciences Center
4200 East, 9th Avenue
Denver, CO 80262
David Greenblatt, M.D.
Professor and Chair
Department of Pharmacology & Experimental Therapeutics
136 Harrison Avenue
Boston, MA 02111
Thomas Kakuda, PharmD
Senior Research Associate
338 Turkshead Lane
Redwood City, CA 94065
Jag H. Khalsa, Ph.D.
Pharmacologist/Health Scientist Administrator
Center on AIDS & Other Medical Consequences of Drug Abuse
National Institute on Drug Abuse
6001 Executive Blvd., Room 5198, MSC 9593
Bethesda, MD 20892-9593
Telephone: (301) 443-1801/2159
Fax: (301) 594-6566
Elinore McCance-Katz, M.D., Ph.D.
Associate Professor of Psychiatry and Epidemiology and Social Medicine
Albert Einstein College of Medicine of Yeshiva University, Department of Psychiatry
Montefiore Medical Center
111 E. 210th Street
Bronx, New York 10467